Clinical trials in Espoo – page 21

385 clinical trials in Espoo, Finland. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FinlandKliinisetTutkimukset.fi

Espoo at a glance

385

clinical trials

Research sites0

Quick filters

385 trials in Espoo

Open in trial search

Meningococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

Registered drugNo placebo

Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

Registered drugNo placebo

Finland

Participants:0–17 years · Healthy volunteers
Substances:Tetanus toxoid
Sponsor:Sanofi Winthrop Industrie

Contact Research Centre

Acute myeloid leukaemia refractory+3

Not recruiting

Study of S227928 Alone and with Venetoclax for Patients with Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Registered drugNo placebo

Study of S227928 Alone and with Venetoclax for Patients with Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Allopurinol
Sponsor:Institut De Recherches Internationales Servier IRIS

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Chronic rhinosinusitis with nasal polyps

Not recruiting

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational

Long‑term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps: an extension study

Investigational

Finland

Participants:18–64 years · 65+ years
Substances:Itepekimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Cytomegalovirus immunisation

Not recruiting

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug

Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40

Registered drug

Finland

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:Sodium Chloride
Sponsor:Moderna Inc.

Contact Research Centre

Hormone-dependent prostate cancer+1

Not recruiting

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug

Finland

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Pfizer Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug

Finland

Participants:18–64 years · 65+ years
Substances:Salbutamol
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

Registered drug

Study of Tozorakimab for Patients with Chronic Obstructive Pulmonary Disease Who Have Symptoms and a History of Flare-ups

Registered drug

Finland

Participants:18–64 years · 65+ years
Substances:Salbutamol Sulfate
Sponsor:AstraZeneca AB

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease

InvestigationalNo placebo

A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease

InvestigationalNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:GSK4527226
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Colitis ulcerative

Not recruiting

Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis

Investigational

Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis

Investigational

Finland

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Colitis ulcerative

Not recruiting

Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis

Investigational

Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis

Investigational

Finland

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Espoo

What the registry says about research in the country

01 Infectious Disease Prevention

Comprehensive research focusing on vaccine development for multiple respiratory viruses, including studies of new formulations against influenza, RSV, and pneumococcal infections. Clinical trials are evaluating innovative immunization approaches for various age groups.

Influenza Vaccines
RSV Prevention
Pneumococcal Protection

Particular emphasis on protecting vulnerable populations such as infants, toddlers, and adults over 60 years old.

02 Cardiovascular Health

Advanced research in cardiovascular medicine, focusing on preventing stroke in atrial fibrillation patients and developing new treatments for acute myocardial infarction. Studies include innovative drug therapies and preventive measures.

Stroke Prevention
Heart Attack Management
Blood Clot Prevention

Trials are investigating new anticoagulants and emergency interventions for heart conditions.

03 Surgical and Specialized Care

Innovative research in surgical procedures and specialized medical conditions, including studies on frostbite treatment, plastic surgery outcomes, and post-operative care protocols.

Surgical Complications
Emergency Medicine
Post-Operative Care

Focus on improving surgical outcomes and developing better treatment protocols for specialized conditions.

Back to Finland All countries